Hyponatremia and/or Hyperkalemia in Patients Treated with the Standard Dose of Trimethoprim-sulfamethoxazole

• Published in: Internal Medicine Vol. 42; no. 8; pp. 665 - 669
• Main Authors: MORI, Honami, KURODA, Yutaka, IMAMURA, Shigeki, TOYODA, Akira, YOSHIDA, Izumi, KAWAKAMI, Masanobu, TABEI, Kaoru
• Format: Journal Article
• Language: English
• Published: Tokyo The Japanese Society of Internal Medicine 01.08.2003; Japanese Society of Internal Medicine
• Subjects: Anti-Infective Agents - administration & dosage; Anti-Infective Agents - adverse effects; Biological and medical sciences; Creatinine - blood; Dose-Response Relationship, Drug; Drug toxicity and drugs side effects treatment; electrolyte disorders; Female; Humans; Hyperkalemia - chemically induced; Hyponatremia - chemically induced; Male; Medical sciences; Middle Aged; Miscellaneous (drug allergy, mutagens, teratogens...); Pharmacology. Drug treatments; Potassium - blood; renal dysfunction; Retrospective Studies; Sodium - blood; TMP-SMX; Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage; Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects; Kidney disease; Human; electrolyte disorders; Hydroelectrolytic balance disorder; Urinary system disease; Renal function; Hyponatremia; TMP- SMX; Trimethoprim; Pharmacology; renal dysfunction; Inorganic element; Hyperkaliemia; Metabolic disorder; Chemotherapy; Sulfamethoxazole; Treatment; Dysfunction; Secondary effect; Antiinfectious; Pharmacokinetics

Objective High-dose trimethoprim-sulfamethoxazole (TMP-SMX) is known to cause hyperkalemia by blocking amiloride-sensitive sodium (Na) channels in distal nephrons. The purpose of this study was to establish whether the standard dose of TMP-SMX could cause electrolyte disorders. Methods and Patients...